Company intelligence / Profile preview

Stargazer Pharmaceuticals

Boston, Massachusetts, United Statesstargazerpharma.com ↗

Ownership: Private
Development stage: Other

Overview

Stargazer Pharmaceuticals, Inc. is developing novel treatment options for rare eye diseases with a primary focus on Stargardt Disease. Its lead candidate, STG‑001, entered Phase 2a clinical trials in late 2020. The company has raised significant Series A funding to advance this program and aims to address unmet needs in inherited retinal disorders. No published results from pivotal studies are available yet.

Therapeutic areas: Ophthalmology
Modalities: Small molecules (specifically, proprietary compound STG-001)
Industry: Biotech

Drug pipeline

1 asset

STG-001

Partnerships

Foundation Fighting Blindness/Retinal Degeneration Fund participated in financing and development collaboration for STG‑001

Beyond the preview

Go deeper on Stargazer Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stargazer Pharmaceuticals.